Potential of urinary biomarkers in early bladder cancer diagnosis

Thomas Lam, Ghulam Nabi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Carcinoma of urinary bladder ranks among the top ten most common cancers worldwide. Approximately 80% of the disease is superficial (limited to mucosa and lamina propria) at the time of presentation. However, the majority of these tumors recur and 15-20% progress into muscle-invasive disease. Cystoscopic surveillance of the urinary bladder remains the standard of care to identify these recurrences on follow-up. Not only is this an invasive procedure, but the sensitivity of cystoscopy can be as low as 70%, so there can be up to 30% of tumors that are missed. Urinary cytology, with recognized limitations, has been used as an adjunct to this procedure, pending discovery of alternate urinary biomarkers. In the past decade there has been tremendous advancement in producing urinary biomarkers for urinary bladder cancer research, reflecting advancements in genomics and proteomics. An ideal biomarker should be able to replace cystoscopic examination and be cost effective. Unfortunately, most of the identified protein or molecular biomarkers have failed this test. This article critically appraises the status of these urinary biomarkers in urinary bladder cancer, in addition to highlighting some of the difficulties in this research area.

Original languageEnglish
Pages (from-to)1105-1115
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume7
Issue number8
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Early Detection of Cancer
Urinary Bladder Neoplasms
Biomarkers
Mucous Membrane
Urinary Bladder
Neoplasms
Cystoscopy
Standard of Care
Genomics
Research
Proteomics
Cell Biology
Carcinoma
Costs and Cost Analysis
Recurrence
Muscles
Proteins

Cite this

Potential of urinary biomarkers in early bladder cancer diagnosis. / Lam, Thomas; Nabi, Ghulam.

In: Expert Review of Anticancer Therapy, Vol. 7, No. 8, 08.2007, p. 1105-1115.

Research output: Contribution to journalArticle

@article{da1713e6df494f77902d655eeb199edf,
title = "Potential of urinary biomarkers in early bladder cancer diagnosis",
abstract = "Carcinoma of urinary bladder ranks among the top ten most common cancers worldwide. Approximately 80{\%} of the disease is superficial (limited to mucosa and lamina propria) at the time of presentation. However, the majority of these tumors recur and 15-20{\%} progress into muscle-invasive disease. Cystoscopic surveillance of the urinary bladder remains the standard of care to identify these recurrences on follow-up. Not only is this an invasive procedure, but the sensitivity of cystoscopy can be as low as 70{\%}, so there can be up to 30{\%} of tumors that are missed. Urinary cytology, with recognized limitations, has been used as an adjunct to this procedure, pending discovery of alternate urinary biomarkers. In the past decade there has been tremendous advancement in producing urinary biomarkers for urinary bladder cancer research, reflecting advancements in genomics and proteomics. An ideal biomarker should be able to replace cystoscopic examination and be cost effective. Unfortunately, most of the identified protein or molecular biomarkers have failed this test. This article critically appraises the status of these urinary biomarkers in urinary bladder cancer, in addition to highlighting some of the difficulties in this research area.",
author = "Thomas Lam and Ghulam Nabi",
year = "2007",
month = "8",
doi = "10.1586/14737140.7.8.1105",
language = "English",
volume = "7",
pages = "1105--1115",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Potential of urinary biomarkers in early bladder cancer diagnosis

AU - Lam, Thomas

AU - Nabi, Ghulam

PY - 2007/8

Y1 - 2007/8

N2 - Carcinoma of urinary bladder ranks among the top ten most common cancers worldwide. Approximately 80% of the disease is superficial (limited to mucosa and lamina propria) at the time of presentation. However, the majority of these tumors recur and 15-20% progress into muscle-invasive disease. Cystoscopic surveillance of the urinary bladder remains the standard of care to identify these recurrences on follow-up. Not only is this an invasive procedure, but the sensitivity of cystoscopy can be as low as 70%, so there can be up to 30% of tumors that are missed. Urinary cytology, with recognized limitations, has been used as an adjunct to this procedure, pending discovery of alternate urinary biomarkers. In the past decade there has been tremendous advancement in producing urinary biomarkers for urinary bladder cancer research, reflecting advancements in genomics and proteomics. An ideal biomarker should be able to replace cystoscopic examination and be cost effective. Unfortunately, most of the identified protein or molecular biomarkers have failed this test. This article critically appraises the status of these urinary biomarkers in urinary bladder cancer, in addition to highlighting some of the difficulties in this research area.

AB - Carcinoma of urinary bladder ranks among the top ten most common cancers worldwide. Approximately 80% of the disease is superficial (limited to mucosa and lamina propria) at the time of presentation. However, the majority of these tumors recur and 15-20% progress into muscle-invasive disease. Cystoscopic surveillance of the urinary bladder remains the standard of care to identify these recurrences on follow-up. Not only is this an invasive procedure, but the sensitivity of cystoscopy can be as low as 70%, so there can be up to 30% of tumors that are missed. Urinary cytology, with recognized limitations, has been used as an adjunct to this procedure, pending discovery of alternate urinary biomarkers. In the past decade there has been tremendous advancement in producing urinary biomarkers for urinary bladder cancer research, reflecting advancements in genomics and proteomics. An ideal biomarker should be able to replace cystoscopic examination and be cost effective. Unfortunately, most of the identified protein or molecular biomarkers have failed this test. This article critically appraises the status of these urinary biomarkers in urinary bladder cancer, in addition to highlighting some of the difficulties in this research area.

U2 - 10.1586/14737140.7.8.1105

DO - 10.1586/14737140.7.8.1105

M3 - Article

VL - 7

SP - 1105

EP - 1115

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 8

ER -